Background. A multicenter study was performed to evaluate the reproducibility of Ceftazidime/Avibactam on a MicroScan Dried Gram Negative MIC (MSDGN) Panel.
Background. The current standard technique for diagnosis of bloodstream infection (BSI) is through the detection of micro-organisms using automated blood culture systems and subsequent phenotypic antimicrobial susceptibilty testing (AST) techniques that require 24-48 hours to generate results. The aim of this study was to evaluate the Accelerate Pheno™ system (AXDX), which utilises fluorescent in situ hybridization and morphokinetic cellular analysis to identify bacteria from positive blood cultures and perform AST in less than 7 hours.
Methods. The Accelerate PhenoTest™ BC kit was used to test 15 gram-negative isolates with a range of AST profiles, from simulated blood cultures. Isolates included 10 target organisms; Escherichia coli (n = 2), Enterobacter sp. (n = 2), Klebsiella sp., Proteus sp., Citrobacter sp., Pseudomonas aeruginosa, Acinetobacter baumannii, Serratia marcescens and 5 non-target organisms. AXDX results were compared with MALDI-ToF MS identification and BD Phoenix™ automated AST results. To evaluate the reproducibility of AXDX analysis, all isolates were tested at two different sites, six in duplicate.
Results. A total of 37 tests were performed. AXDX correctly identified 90% (9/10) of the target organisms, and correctly identified 100% (5/5) of non-target organisms as such. One isolate of Citrobacter sp. was initially misidentified as Enterobacter sp. but was correctly identified twice on repeat testing. The AST results demonstrated 93% (244/262) essential agreement (MIC within <1 dilution) and 90% (237/262) categorical agreement (same S/I/R interpretation) compared with conventional laboratory methods. For AST results, between-site reproducibility (MIC within <1 dilution) was 97%.
Conclusion. The Accelerate PhenoTest™ BC kit can provide rapid identification alongside phenotypic AST results direct from positive blood cultures. In this study, the assay demonstrated high reproducibility and good correlation with conventional laboratory methods. By reducing the time to AST results the Accelerate Pheno™ system has the potential to produce actionable results for the management of BSI and enable earlier escalation or de-escalation of antibiotic therapy. This also has the potential to improve patient outcomes by reducing morbidity and mortality. Background. Delayed reporting of antibiotic susceptibility results impacts the treatment of patients with bacteremia. We evaluated the sensitivity and specificity of DST of GNB from pellets used for rapid identification (ID) directly from +BC.
Methods. Pellets from 1.5 mL of +BC in our lab have been used for the direct speciation of bacteria. For 109 samples identified as aerobic GNB on these pellets, the remainder of the sample was suspended in 0.45% NaCl to a standard density of 0.5 McFarland. Specimens were then processed using Vitek2 TM N216 cards according to the manufacturer's instructions. Results were compared with those from susceptibility testing from plate subculture 18 -24 hours later. Antibiotics not reported on blood isolates from this card including were not included in the analysis. To increase the number of antibiotic-resistant organisms (ARO), 35 highly resistant GNB were seeded into BC and processed as above.
Results. Clinical specimens tested included 80 E. coli (EC), 14 K. pneumoniae, 5 K. oxytoca, 3 E. cloacae, and 2 P. aeruginosa, 2 P. mirabilis, and one each of S. marscesens, S. typhi, P. vulgaris, and R. planticola. DST results were available on average 24.8 (95% CI 23.4 -26.2) hours earlier. Of 235 antibiotic resistant results, there were 2 very major errors (VME) (0.85%) with DST -both in EC against cefepime (CPM). These isolates flagged as possible ESBL-producers based on the ceftazidime (CTAZ) or ceftriaxone (CTRX) DST. Two major errors (MAE) occurred with trimpethoprim-sulfamethoxazole (0.85%). Minor errors occurred in 17 cases all within one dilution of the standard MIC. All of the other tests resulted in categorical or essential agreement.
On the ARO tested, there were 405 antibiotic resistant results on standard testing. In this set, there were 10 VME (0.25%); including 1 amikacin, 2 CPM, 1 CTRX, 6 meropenem (MERO). Mechanisms of resistance in these VME included organisms with VIM (6), OXA (3), and KPC (1) genes. All VME with CPM, MERO, and CTRX were flagged as potential ESBL-producers base on the CTAZ result. One MAE with cefoxitin.
Conclusion. DST from BC produces reliable results 24 hour sooner than standard testing. Isolates flagged for potential resistance to thirdgeneration cephalosporin and/ or carbapenem on DST need further testing.
Disclosures. Background. This study evaluated AXDX (uses FISH/real-time microscopy to obtain ID/AST direct from +BC in <7h) for accuracy against reference mass spectrometry (MS, VITEK ® MS, bioMérieux) and broth microdilution (BMD), respectively. AXDX TAT was timed against current reporting for ID using MS and VITEK ® 2 (VT2, bioMérieux) for AST (VT2 data not presented).
Methods. : 68.7-82.7) , ME/mE (CFZ: 5.1-16.8; CAZ: 10-21.9; TZP: 9.2-20.8)]. VME were not evaluable (NE) for TZP, ETP, MEM, or AN due to insufficient numbers of GNB resistant to these agents. ID/AST TAT means (ranges) for AXDX were 1:21h (1:19-1:24h)/6:38h (6:30-6:59h) conmpared to MS/VT2 of 8:49h (2:49-76:48h)/38:23h (19:44-64:22h), respectively; paired t-tests, P < 0.0001/P < 0.0001; difference of means: 8:17h (95% CI:6:55-9:38h)/28:41h (95% CI:26:53-30:29h)].
Conclusion. These data suggest AXDX will significantly reduce ID/AST TAT in GNB bacteremia (ID: 8:49h to 1:21h; AST: 38:23h to 6:38h) with potential to significantly improve patient outcomes. Acceptable accuracy was achieved for ID and AST for most agents. A limitation was the lack of GNB causing bacteremia with resistance to AN, TZP, ETP or MEM in during evaluation. Background. Laboratory turn-around-times (TATs) for identification (ID) and antimicrobial susceptibilities (AST) can delay prescription of adequate and/or optimal antimicrobial (ABX) therapy in septic patients leading to poor outcomes. The Accelerate Pheno™ system (Accelerate Diagnostics, USA) (AXDX) is a rapid ID and AST system with potential to improve TATs.
Methods. 70 prospective non-duplicate blood cultures with Gram-negative bacilli were loaded onto AXDX. AXDX TATs were compared with TATs associated with current methods [ID by MALDI-TOF Vitek® MS (bioMérieux) using short-incubation plates, AST by Vitek® 2 (bioMérieux)]; modified current methods (calling MALDI ID and Vitek® 2 AST and releasing Vitek® 2 AST prior to purity plate review); and former methods (ID and AST by Vitek® 2), the latter determined by laboratory data review of 134 blood cultures from 2011. Impact of the change in TAT on ABX use was determined by chart review.
Results. Gram stain, ID and AST results led to tailoring of ABX in 88.6% of patients impacting 22.9%, 31.4%, and 64.3% of patients at 2.5h, 19.0h, and 62.1h respectively post positive blood culture using current methods (Figures 1 and 2) . AXDX generated the shortest ID and AST TATs with the potential to shorten the time to ABX tailoring due to ID and AST to 1.3h and 6.7h respectively. Calling ID and AST results directly to physicians or releasing AST results from Vitek® 2 prior to purity plate review would also have the potential to significantly improve time to ABX change compared with current methods.
Conclusion. Among the methods compared, AXDX has the greatest potential impact on time to appropriate antibiotics following reports of ID and AST results in Gram-negative bacilli bloodstream infections. Calling ID or AST results directly to physicians could also improve time to ABX tailoring. Impact of engaging antimicrobial stewardship teams requires further study.
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